Search This Blog

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln

The acquisition is in line with Novo's strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth. Under the agreement, ...


No comments:

Post a Comment

Follow by Email